ARQT – arcutis biotherapeutics, inc. - common stock (US:NASDAQ)
Stock Stats
News
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis [Yahoo! Finance]
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
Arcutis Biotherapeutics announces termination of promotion agreement with Kowa [Yahoo! Finance]
Arcutis Biotherapeutics (NASDAQ:ARQT) had its price target raised by analysts at Needham & Company LLC from $30.00 to $31.00. They now have a "buy" rating on the stock.
Form 4 Arcutis Biotherapeutics, For: Feb 02 Filed by: Matsuda Masaru
Form 4 Arcutis Biotherapeutics, For: Feb 02 Filed by: Burnett Patrick
Form 4 Arcutis Biotherapeutics, For: Feb 02 Filed by: Watanabe Todd
Form 4 Arcutis Biotherapeutics, For: Feb 02 Filed by: Vairavan Latha
Form 4 Arcutis Biotherapeutics, For: Feb 02 Filed by: Welgus Howard G.
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.